Data gathered: July 5
AI Stock Analysis - Vanda Pharmaceuticals (VNDA)
Analysis generated February 26, 2025. Powered by Chat GPT.
Vanda Pharmaceuticals Inc. (VNDA) is a biopharmaceutical company focused on the development and commercialization of therapies to address high unmet medical needs. With a portfolio that includes treatments for central nervous system disorders, the company has shown a degree of specialization that sets it apart in its niche.
Stock Alerts - Vanda Pharmaceuticals (VNDA)
 |
Vanda Pharmaceuticals | July 1 Employee Rating is up by 2.9% over the last month. |
|
Vanda Pharmaceuticals | June 17 Insider Alert: Mitchell Stephen Ray is selling shares |
|
Vanda Pharmaceuticals | June 10 Employee Rating is up by 2.9% over the last month. |
|
Vanda Pharmaceuticals | May 20 Insider Alert: Polymeropoulos Mihael Hristos is buying shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Vanda Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 108 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 29,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 49 | Sign up | Sign up | Sign up |
| Patents | 121 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 29 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,364 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,508 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 43 | Sign up | Sign up | Sign up |
| Linkedin Employees | 515 | Sign up | Sign up | Sign up |
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
| Price | $4.97 |
| Target Price | Sign up |
| Volume | 293,730 |
| Market Cap | $293M |
| Year Range | $3.92 - $5.46 |
| Dividend Yield | 0% |
| PE Ratio | 126 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Vanda Pharmaceuticals Inc.(NasdaqGM: VNDA) added to Russell 2000 Value-Defensive IndexJune 30 - Finnhub |
|
Vanda Pharmaceuticals Inc.(NasdaqGM: VNDA) added to Russell 2000 Defensive IndexJune 29 - Finnhub |
|
 |
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by Wall Street Zen to Hold RatingJune 15 - ETF Daily News |
 |
Brokers Offer Predictions for VNDA FY2026 EarningsJune 11 - ETF Daily News |
Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2SJune 9 - Finnhub |
|
 |
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 9 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 50M | 3.5M | 47M | -29M | -41M | -0.500 |
| Q4 '24 | 53M | 2.6M | 49M | -4.9M | -8.3M | -0.084 |
| Q3 '24 | 48M | 2.6M | 45M | -5.3M | -9M | -0.090 |
| Q2 '24 | 50M | 4.5M | 46M | -4.5M | -8.2M | -0.080 |
| Q1 '24 | 47M | 5.5M | 42M | -4.1M | -7M | -0.072 |
Insider Transactions View All
| Mitchell Stephen Ray filed to sell 97,082 shares at $4.6. June 16 '25 |
| Polymeropoulos Mihael Hristos filed to buy 2,325,731 shares at $4.4. May 21 '25 |
| Polymeropoulos Mihael Hristos filed to buy 2,325,250 shares at $4.4. May 21 '25 |
| Polymeropoulos Mihael Hristos filed to buy 2,315,731 shares at $4.2. May 19 '25 |
| Polymeropoulos Mihael Hristos filed to buy 2,295,731 shares at $5. March 6 '25 |
Similar companies
Read more about Vanda Pharmaceuticals (VNDA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Vanda Pharmaceuticals?
The Market Cap of Vanda Pharmaceuticals is $293M.
What is Vanda Pharmaceuticals' PE Ratio?
As of today, Vanda Pharmaceuticals' PE (Price to Earnings) ratio is 126.
What is the current stock price of Vanda Pharmaceuticals?
Currently, the price of one share of Vanda Pharmaceuticals stock is $4.97.
How can I analyze the VNDA stock price chart for investment decisions?
The VNDA stock price chart above provides a comprehensive visual representation of Vanda Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vanda Pharmaceuticals shares. Our platform offers an up-to-date VNDA stock price chart, along with technical data analysis and alternative data insights.
Does VNDA offer dividends to its shareholders?
As of our latest update, Vanda Pharmaceuticals (VNDA) does not offer dividends to its shareholders. Investors interested in Vanda Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Vanda Pharmaceuticals?
Some of the similar stocks of Vanda Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.